ICMR’s Initiatives in Phase-1 Clinical Trials for Zika Vaccine and CAR-T Cell Therapy
ICMR Strengthens Clinical Research Initiatives
In a significant step towards bolstering India’s clinical research capabilities, the Indian Council of Medical Research (ICMR) has signed Memorandum of Agreements (MoAs) with key industry players to conduct First-in-Human Phase-1 Clinical Trials for four promising therapeutic candidates under its Phase 1 Clinical Trial Network.
Strategic Collaborations in Healthcare
As part of these strategic collaborations, ICMR will:
- Work with Aurigene Oncology Limited on a small molecule for multiple myeloma.
- Partner with Indian Immunologicals Limited for Zika vaccine development.
- Coordinate a seasonal influenza vaccine trial with Mynvax Private Limited.
- Explore advancements in CAR-T cell therapy for chronic lymphocytic leukemia with ImmunoACT.
Union Health Minister J P Nadda lauded the partnerships, calling them a pivotal step towards enhancing affordable healthcare options and driving healthcare innovation in India.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.